Users of popular GLP-1 weight loss drugs will pay less next year under a new plan Novo Nordisk announced Tuesday.<\/p>\n
Wegovy, Ozempic and Rybelsus will have a list price of $675 per month starting Jan. 1, 2027, the Danish pharmaceutical company said.<\/p>\n
What You Need To Know<\/p>\n
Wegovy, Ozempic and Rybelsus will have a list price of $675 per month starting Jan. 1, 2027, the Danish pharmaceutical company Novo Nordisk said Tuesday
\n
The new prices apply to all doses and are about 50% lower for Wegovy and 35% lower for Ozempic compared with their current pricing
\n
The move is seen as an attempt to make the medication more available to patients who pay for it through their insurance based on list prices, which are currently $1,349 for Wegovy and $1,028 for Ozempic and Rybelsus
\nThe lower list prices will not impact the prices consumers pay for the drugs directly outside of insurance
\n
About 15.5 million U.S. adults have used injectable Type 2 diabetes medications for weight loss, according to a 2024 Gallup poll<\/p>\n
The new prices apply to all doses and are about 50% lower for Wegovy and 35% lower for Ozempic compared with their current pricing.<\/p>\n
\u201cPrivate and public payers, as well as patients, want access and have been calling for lower list prices,\u201d Jamey\u00a0Millar,\u00a0Novo Nordisk’s executive vice president of U.S. operations, said in a statement. \u201cOur actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.\u201d<\/p>\n
The move is seen as an attempt to make the medication more available to patients who pay for it through their insurance based on list prices, which are currently $1,349 for Wegovy, $1,028 for Ozempic and $998 for Rybelsus, according to the telehealth provider Ro.co. The lower list prices will not impact the prices consumers pay for the drugs directly outside of insurance, Novo Nordisk said.<\/p>\n
In the United States, about 42% of adults over the age of 20 are obese, according to the U.S. Centers for Disease Control and Prevention. Adults with obesity often have serious chronic conditions such as diabetes and heart disease.<\/p>\n
About 15.5 million U.S. adults have used injectable Type 2 diabetes medications for weight loss, according to a 2024 Gallup poll.<\/p>\n
GLP-1 treatments work by mimicking the natural hormone glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and suppress appetite and is used to treat Type 2 diabetes and obesity.<\/p>\n
Millar said more than 100 million people in the U.S. live with obesity and over 35 million people have Type 2 diabetes.<\/p>\n
Wegovy is a weight-loss drug available as both an injectable and a tablet. The injectable drug Ozempic and the oral medication Rybelsus are designed to treat Type 2 diabetes but are also used for weight loss.<\/p>\n
Since 2019, GLP-1 treatments for non-diabetic purposes have increased 700%, according to the investment analysis firm Morningstar Equity Research, which projects the market for GLP-1s will reach $180 billion in 2034.<\/p>\n
Novo Nordisk is a top competitor of Eli Lilly, maker of the GLP-1 weight-loss drugs Zepbound and Mounjaro, which cost $1,086 and $1,069 respectively, according to Ro.co. Other pharmaceutical behemoths, including Pfizer, Roche, Amgen and AstraZeneca, are expected to begin making GLP-1s between 2027 and 2032, Morningstar said. It expects more price declines for GLP-1s in the future as more companies enter the market.<\/p>\n
Last year, Novo Nordisk and Eli Lilly both signed the Trump administration\u2019s most-favored-nation drug-pricing policy, which aims to lower prescription drug prices to the same rate as other developed countries.<\/p>\n
Under the deal, the companies said they would provide state Medicaid programs with most-favored nation prices not only for GLP-1s but all new medicines they bring to the market.<\/p>\n","protected":false},"excerpt":{"rendered":"Users of popular GLP-1 weight loss drugs will pay less next year under a new plan Novo Nordisk…\n","protected":false},"author":2,"featured_media":23458,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[15603,15605,15606,15604,393,15608,38,15609,272,15607,2508],"class_list":["post-23457","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-all-markets-rank-everywhere","tag-app-for-your-consideration","tag-app-health","tag-app-top-stories","tag-health","tag-health-and-medicine","tag-news","tag-nnt","tag-novo-nordisk","tag-susan-carpenter","tag-top-stories"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/23457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=23457"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/23457\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/23458"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=23457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=23457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=23457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}